BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
This story is reported by PR Newswire. Read what other outlets are saying below, then open the original report for full details.